Literature DB >> 17222883

Binding and neutralization efficiencies of monoclonal antibodies, Fab fragments, and scFv specific for L1 epitopes on the capsid of infectious HPV particles.

Timothy D Culp1, Christin M Spatz, Cynthia A Reed, Neil D Christensen.   

Abstract

We compared the neutralization abilities of individual monoclonal antibodies (MAb) of two large panels reactive with L1 epitopes of HPV-11 or HPV-16. Binding titers were compared using both L1-only VLPs and L1/L2 pseudovirions. While the VLPs were antigenically similar to the pseudovirions, clear differences in the surface exposure of some epitopes were evident with the HPV-16 particles. To determine whether all antibody binding events are equivalent in their neutralizing effect on infectious HPV virions or pseudovirions, the binding and neutralization titers for individual MAbs were used to calculate the relative neutralization efficiency for each antibody. HPV neutralization was achieved by all MAbs capable of strong binding to either linear or conformation-sensitive epitopes on pseudovirus particles. Our data suggest, however, that some L1 epitopes may be more neutralization-sensitive than other surface epitopes, in that successful infection can be blocked by varying degrees of epitope saturation. Additionally, the effective neutralization of virions by several monovalent Fab fragments and single-chain variable fragments (scFv) demonstrates that viral neutralization does not require HPV particle aggregation or L1 crosslinking. Identification of capsid protein structures rich in neutralization-sensitive epitopes may aid in the development of improved recombinant vaccines capable of eliciting effective and long-term antibody-mediated protection against multiple HPV types.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17222883      PMCID: PMC2040078          DOI: 10.1016/j.virol.2006.12.002

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  46 in total

1.  Keratinocyte-secreted laminin 5 can function as a transient receptor for human papillomaviruses by binding virions and transferring them to adjacent cells.

Authors:  Timothy D Culp; Lynn R Budgeon; M Peter Marinkovich; Guerrino Meneguzzi; Neil D Christensen
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

2.  Mapping of linear epitopes of human papillomavirus type 16: the L1 and L2 open reading frames.

Authors:  J Dillner; L Dillner; G Utter; C Eklund; A Rotola; S Costa; D DiLuca
Journal:  Int J Cancer       Date:  1990-03-15       Impact factor: 7.396

3.  Laboratory production in vivo of infectious human papillomavirus type 11.

Authors:  J W Kreider; M K Howett; A E Leure-Dupree; R J Zaino; J A Weber
Journal:  J Virol       Date:  1987-02       Impact factor: 5.103

4.  Monoclonal antibody-mediated neutralization of infectious human papillomavirus type 11.

Authors:  N D Christensen; J W Kreider; N M Cladel; S D Patrick; P A Welsh
Journal:  J Virol       Date:  1990-11       Impact factor: 5.103

5.  Against which human papillomavirus types shall we vaccinate and screen? The international perspective.

Authors:  Nubia Muñoz; F Xavier Bosch; Xavier Castellsagué; Mireia Díaz; Silvia de Sanjose; Doudja Hammouda; Keerti V Shah; Chris J L M Meijer
Journal:  Int J Cancer       Date:  2004-08-20       Impact factor: 7.396

6.  Quantitative RT-PCR assay for HPV infection in cultured cells.

Authors:  Timothy D Culp; Neil D Christensen
Journal:  J Virol Methods       Date:  2003-08       Impact factor: 2.014

7.  Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18.

Authors:  Diana V Pastrana; Christopher B Buck; Yuk-Ying S Pang; Cynthia D Thompson; Philip E Castle; Peter C FitzGerald; Susanne Krüger Kjaer; Douglas R Lowy; John T Schiller
Journal:  Virology       Date:  2004-04-10       Impact factor: 3.616

8.  Efficient intracellular assembly of papillomaviral vectors.

Authors:  Christopher B Buck; Diana V Pastrana; Douglas R Lowy; John T Schiller
Journal:  J Virol       Date:  2004-01       Impact factor: 5.103

9.  Assembled baculovirus-expressed human papillomavirus type 11 L1 capsid protein virus-like particles are recognized by neutralizing monoclonal antibodies and induce high titres of neutralizing antibodies.

Authors:  N D Christensen; R Höpfl; S L DiAngelo; N M Cladel; S D Patrick; P A Welsh; L R Budgeon; C A Reed; J W Kreider
Journal:  J Gen Virol       Date:  1994-09       Impact factor: 3.891

10.  Characterization of HPV16 L1 loop domains in the formation of a type-specific, conformational epitope.

Authors:  Vanessa A Olcese; Yan Chen; Richard Schlegel; Hang Yuan
Journal:  BMC Microbiol       Date:  2004-07-19       Impact factor: 4.465

View more
  22 in total

Review 1.  The papillomavirus major capsid protein L1.

Authors:  Christopher B Buck; Patricia M Day; Benes L Trus
Journal:  Virology       Date:  2013-06-22       Impact factor: 3.616

2.  Naturally Occurring Capsid Protein Variants of Human Papillomavirus Genotype 31 Represent a Single L1 Serotype.

Authors:  Sara L Bissett; Anna Godi; Maxime J J Fleury; Antoine Touze; Clementina Cocuzza; Simon Beddows
Journal:  J Virol       Date:  2015-05-20       Impact factor: 5.103

3.  Structural comparison of four different antibodies interacting with human papillomavirus 16 and mechanisms of neutralization.

Authors:  Jian Guan; Stephanie M Bywaters; Sarah A Brendle; Hyunwook Lee; Robert E Ashley; Alexander M Makhov; James F Conway; Neil D Christensen; Susan Hafenstein
Journal:  Virology       Date:  2015-05-19       Impact factor: 3.616

4.  Generation and characterization of neutralizing monoclonal antibodies against baculo-expressed HPV 16 VLPs.

Authors:  P Vidyasagar; V N Sridevi; S Rajan; A Praveen; A Srikanth; G Abhinay; V Siva Kumar; R R Verma; L Rajendra
Journal:  Eur J Microbiol Immunol (Bp)       Date:  2014-03-14

5.  Virus-like particles and capsomeres are potent vaccines against cutaneous alpha HPVs.

Authors:  Tilo Senger; Lysann Schädlich; Sonja Textor; Corinna Klein; Kristina M Michael; Christopher B Buck; Lutz Gissmann
Journal:  Vaccine       Date:  2009-12-08       Impact factor: 3.641

6.  Detection of human papillomavirus type 31-neutralizing antibodies from naturally infected patients by an assay based on intracellular assembly of luciferase-expressing pseudovirions.

Authors:  Maxime J J Fleury; Antoine Touzé; Silvia de Sanjosé; F Xavier Bosch; Joellen Klaustermeiyer; Pierre Coursaget
Journal:  Clin Vaccine Immunol       Date:  2007-11-07

Review 7.  Anti-Ebola therapies based on monoclonal antibodies: current state and challenges ahead.

Authors:  Everardo González-González; Mario Moisés Alvarez; Alan Roberto Márquez-Ipiña; Grissel Trujillo-de Santiago; Luis Mario Rodríguez-Martínez; Nasim Annabi; Ali Khademhosseini
Journal:  Crit Rev Biotechnol       Date:  2015-11-26       Impact factor: 8.429

8.  Characterization of virus-like particles in GARDASIL® by cryo transmission electron microscopy.

Authors:  Qinjian Zhao; Clinton S Potter; Bridget Carragher; Gabriel Lander; Jaime Sworen; Victoria Towne; Dicky Abraham; Paul Duncan; Michael W Washabaugh; Robert D Sitrin
Journal:  Hum Vaccin Immunother       Date:  2013-12-03       Impact factor: 3.452

9.  The U4 Antibody Epitope on Human Papillomavirus 16 Identified by Cryo-electron Microscopy.

Authors:  Jian Guan; Stephanie M Bywaters; Sarah A Brendle; Hyunwook Lee; Robert E Ashley; Neil D Christensen; Susan Hafenstein
Journal:  J Virol       Date:  2015-09-23       Impact factor: 5.103

10.  Neutralization of human papillomavirus with monoclonal antibodies reveals different mechanisms of inhibition.

Authors:  Patricia M Day; Cynthia D Thompson; Christopher B Buck; Yuk-Ying S Pang; Douglas R Lowy; John T Schiller
Journal:  J Virol       Date:  2007-06-06       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.